Encouragement-Induced Real-World Upper Limb Use after Stroke by a Tracking and Feedback Device: A Study Protocol for a Multi-Center, Assessor-Blinded, Randomized Controlled Trial by Held, Jeremia P O et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2018
Encouragement-Induced Real-World Upper Limb Use after Stroke by a
Tracking and Feedback Device: A Study Protocol for a Multi-Center,
Assessor-Blinded, Randomized Controlled Trial
Held, Jeremia P O; Luft, Andreas R; Veerbeek, Janne M
Abstract: Introduction Retraining the paretic upper limb after stroke should be intense and specific
to be effective. Hence, the best training is daily life use, which is often limited by motivation and ef-
fort. Tracking and feedback technology have the potential to encourage self-administered, context-specific
training of upper limb use in the patients’ home environment. The aim of this study is to investigate post-
intervention and long-term effects of a wrist-worn activity tracking device providing multimodal feedback
on daily arm use in hemiparetic subjects beyond 3 months post-stroke. Methods and analysis A prospec-
tive, multi-center, assessor-blinded, Phase 2 randomized controlled trial with a superiority framework.
Sixty-two stroke patients will be randomized in two groups with a 1:1 allocation ratio, stratified based on
arm paresis severity (Fugl-Meyer Assessment-Upper Extremity subscale <32 and ￿32). The experimental
group receives a wrist-worn activity tracking device providing multimodal feedback on daily arm use for
6 weeks. Controls wear an identical device providing no feedback. : 31 participants per group, based
on a difference of 0.75±1.00 points on the Motor Activity Log-14 Item Version, Amount of Use subscale
(MAL-14 AOU), 80% power, two-sided alpha of 0.05, and a 10% attrition rate. : primary outcome is
the change in patient-reported amount of daily life upper limb use (MAL-14 AOU) from baseline to
post-intervention. Secondary outcomes are change in upper limb motor function, upper limb capacity,
global disability, patient-reported quality of daily life upper limb use, and quality of life from baseline
to post-intervention and 6-week follow-up, as well as compliance, activity counts, and safety. Discussion
The results of this study will show the possible efficacy of a wrist-worn tracking and feedback device on
patient-reported amount of daily life upper limb use. Ethics and dissemination The study is approved
by the Cantonal Ethics Committees Zurich, and Northwest and Central Switzerland (BASEC-number
2017-00948) and registered in https://clinicaltrials.gov (NCT03294187) before recruitment started. This
study will be carried out in compliance with the Declaration of Helsinki, ICH-GCP, ISO 14155:2011,
and Swiss legal and regulatory requirements. Dissemination will include submission to a peer-reviewed
journal, patient and healthcare professional magazines, and congress presentations.
DOI: https://doi.org/10.3389/fneur.2018.00013
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-159915
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0)
License.
Originally published at:
Held, Jeremia P O; Luft, Andreas R; Veerbeek, Janne M (2018). Encouragement-Induced Real-World
Upper Limb Use after Stroke by a Tracking and Feedback Device: A Study Protocol for a Multi-Center,
Assessor-Blinded, Randomized Controlled Trial. Frontiers in Neurology, 9:13.
DOI: https://doi.org/10.3389/fneur.2018.00013
2
January 2018 | Volume 9 | Article 131
CliniCal Study ProtoCol
published: 25 January 2018
doi: 10.3389/fneur.2018.00013
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Valerie Moyra Pomeroy, 
University of East Anglia, 
United Kingdom
Reviewed by: 
David Ian Anderson, 
San Francisco State University, 
United States  
Catherine Disselhorst-Klug, 
RWTH Aachen University, Germany
*Correspondence:
Jeremia P. O. Held  
jeremia.held@uzh.ch
Specialty section: 
This article was submitted to Stroke, 
a section of the journal 
Frontiers in Neurology
Received: 01 November 2017
Accepted: 09 January 2018
Published: 25 January 2018
Citation: 
Held JPO, Luft AR and Veerbeek JM 
(2018) Encouragement-Induced Real-
World Upper Limb Use after Stroke 
by a Tracking and Feedback Device: 
A Study Protocol for a Multi-Center, 
Assessor-Blinded, Randomized 
Controlled Trial. 
Front. Neurol. 9:13. 
doi: 10.3389/fneur.2018.00013
Encouragement-induced real-World 
upper limb use after Stroke by a 
tracking and Feedback device:  
a Study Protocol for a Multi-Center, 
assessor-Blinded, randomized 
Controlled trial
Jeremia P. O. Held1,2,3*, Andreas R. Luft1,2 and Janne M. Veerbeek1,2
1 Division of Vascular Neurology and Neurorehabilitation, Department of Neurology, University of Zurich and University 
Hospital Zurich, Zurich, Switzerland, 2 Cereneo, center for Neurology and Rehabilitation, Vitznau, Switzerland, 3 Biomedical 
Signals and Systems, MIRA – Institute for Biomedical Technology and Technical Medicine, University of Twente, Enschede, 
Netherlands
introduction: Retraining the paretic upper limb after stroke should be intense and 
specific to be effective. Hence, the best training is daily life use, which is often limited by 
motivation and effort. Tracking and feedback technology have the potential to encourage 
self-administered, context-specific training of upper limb use in the patients’ home envi-
ronment. The aim of this study is to investigate post-intervention and long-term effects 
of a wrist-worn activity tracking device providing multimodal feedback on daily arm use 
in hemiparetic subjects beyond 3 months post-stroke.
Methods and analysis: A prospective, multi-center, assessor-blinded, Phase 2 ran-
domized controlled trial with a superiority framework. Sixty-two stroke patients will be 
randomized in two groups with a 1:1 allocation ratio, stratified based on arm paresis 
severity (Fugl-Meyer Assessment—Upper Extremity subscale <32 and ≥32). The 
experimental group receives a wrist-worn activity tracking device providing multimodal 
feedback on daily arm use for 6 weeks. Controls wear an identical device providing no 
feedback. Sample size: 31 participants per group, based on a difference of 0.75±1.00 
points on the Motor Activity Log—14 Item Version, Amount of Use subscale (MAL—14 
AOU), 80% power, two-sided alpha of 0.05, and a 10% attrition rate. Outcomes: primary 
outcome is the change in patient-reported amount of daily life upper limb use (MAL—14 
AOU) from baseline to post-intervention. Secondary outcomes are change in upper limb 
motor function, upper limb capacity, global disability, patient-reported quality of daily 
life upper limb use, and quality of life from baseline to post-intervention and 6-week 
follow-up, as well as compliance, activity counts, and safety.
discussion: The results of this study will show the possible efficacy of a wrist-worn 
tracking and feedback device on patient-reported amount of daily life upper limb use.
Ethics and dissemination: The study is approved by the Cantonal Ethics Committees 
Zurich, and Northwest and Central Switzerland (BASEC-number 2017-00948) and 
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registered in https://clinicaltrials.gov (NCT03294187) before recruitment started. This 
study will be carried out in compliance with the Declaration of Helsinki, ICH-GCP, ISO 
14155:2011, and Swiss legal and regulatory requirements. Dissemination will include 
submission to a peer-reviewed journal, patient and healthcare professional magazines, 
and congress presentations.
Keywords: stroke, upper limb, rehabilitation, movement sensor, feedback, daily life
introduCtion
Although medical interventions and care for stroke patients have 
been improving tremendously during the last decades, stroke still 
remains one of the main causes of disease burden globally (1, 2). 
Frequently reported limitations after stroke are impairments of 
upper limb motor function and activities, which is present in 80% 
of the acute stroke patients (3, 4). Recovery of post-stroke impair-
ments mainly occurs within the first 3 months after stroke and 
plateaus thereafter (5, 6). Although the presence of a plateau phase 
implies that patients have reached a stable situation, a functional 
decline has been shown on the long term (i.e., learned-non-use) 
(7). This underlines the importance of continued practice beyond 
the first 3 months post-stroke, with the aim to maintain the levels 
achieved during earlier rehabilitation (8).
Key elements that characterize effective stroke rehabilitation 
interventions are intensity of practice, and task- and context-
specificity (9, 10). Provision of feedback is another important 
ingredient for effective motor learning after stroke (11). In 
the last decade, rehabilitation technology has enabled higher 
intensity of practice and new methods of feedback. Examples of 
applied technologies for the upper limb are robotics and virtual 
reality (12, 13). However, these interventions often lack context-
specificity, as the training is almost always performed in a clinic 
and to date, a beneficial effect on what patients actually do with 
their paretic upper limb in their daily lives has not been reported. 
Furthermore, many of these technological developments require a 
high-financial investment in terms of costs and human resources. 
Recent developments in the field of tracking and feedback tech-
nology have provided low-cost tools (e.g., sensors) that incor-
porate key elements for effective stroke rehabilitation outside 
the clinic. These tracking and feedback tools have the potential 
to motivate patients to use their paretic upper limb in daily life 
while they are in their home environment. With that, they pos-
sibly are able to maintain or even improve gains made during the 
intensive rehabilitation period and facilitate a translation to the 
patients’ daily life. These tools most often rely on accelerometer 
data, which have been found to be reliable and valid in stroke 
subjects (14, 15), and correlate well with patient-reported upper 
limb use in daily life as assessed by the Motor Activity Log (16). 
Previous research has shown that stroke survivors have a high 
adherence to wearing accelerometer devices at home (17) and 
report good acceptance levels and high usability scores (18, 19). 
These tracking devices can be used to give augmented feedback 
regarding movement outcomes or success rate (i.e., knowledge 
of results) (20, 21). Knowledge of results is an external form of 
feedback that can encourage a patient to reach a certain goal, such 
as using the paretic upper limb at least a pre-defined number of 
times a day (e.g., 100) when performing daily life activities. In 
this example, the external feedback given by the trackers could 
enhance a patient’s intrinsic motivation to improve the number of 
times he or she uses the upper limb during the day. The provided 
feedback should be tailored to the individual needs to increase 
motivation, compliance, and effectiveness. There are various 
feedback modalities available, such as vibrotactile, visual, and 
auditory feedback. A recent study reported that stroke patients 
preferred vibrotactile feedback over visual and auditory feedback 
(19). However, the application of visual feedback on a smartphone 
has also been indicated as an effective way of delivering feedback 
(22). With that, the optimal medium for providing feedback 
remains unknown.
Study aim
The primary aim of this study is to determine the post-intervention 
and long-term effects of wearing a wrist-worn, commercially 
available tracking device that provides multimodal feedback for 
6 weeks on patient-reported amount of paretic upper limb use in 
daily life in hemiparetic subjects beyond 3 months after stroke, 
when compared with a control group receiving an identical looking 
device providing no feedback. The secondary aims are to examine 
the compliance to use the device, and explore the effect on motor 
function of the paretic upper limb, upper limb capacity, patient-
reported quality of paretic upper limb use in daily life, global 
disability, health-related quality of life, and during the 6-week 
intervention, the compliance and activity counts of the paretic 
and non-paretic upper limb. As a measure of safety, the incidence 
and severity of side effects related to the long-time wrist-worn 
feedback intervention during the study period will be investigated. 
Furthermore, the Minimal Clinical Important Difference (MCID) 
of the Amount of Use (AOU) subscale of the Motor Activity 
Log—14 Item Version (MAL—14) will be established.
MEtHodS and analySiS
Study design
The present study is a multi-center, assessor-blinded, Phase 2 ran-
domized controlled trial with a superiority framework, including 
two parallel study arms. Patients will be informed about the study, 
including its procedures, and enrolled by a study team member. 
Randomization will be stratified based on severity of upper limb 
paresis [Fugl-Meyer Assessment—Upper Extremity subscale 
(FMA-UE) <32 and ≥32] (23) with a 1:1 allocation ratio. At the 
time of patient registration in the centralized web-based database 
(REDCap™), patients will be given a unique study identification 
number that is linked to a computer-generated randomization 
FigurE 1 | Participant time line. Legend: R, randomization; T0, baseline assessment; T1, post-intervention assessment; T2, follow-up assessment.
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assignment using a pre-set list of random numbers. The pre-set 
list of random numbers was generated based on a seed number 
(SAS® 9.3) and balanced based on the stratification in blocks of 4. 
Randomization is performed by a study member not involved in 
the outcome assessments.
An Emergency Code Break will be available to the investi-
gator. This Code Break should only be opened in emergency 
situations when the identity of the investigational product must 
be known by the investigator in order to provide appropriate 
medical treatment.
This study was approved by the Cantonal Ethics Committee 
Zurich and Cantonal Ethics Committee Northwest and Central 
Switzerland (BASEC-number 2017-00948). All subjects will give 
written informed consent in accordance with the Declaration of 
Helsinki. The trial is registered at https://clinicaltrials.gov, unique 
identifier NCT03294187 prior to patient recruitment.
Eligibility Criteria/Participants
This study includes subjects aged 18  years or older who have 
experienced a unilateral stroke more than 90 days ago and have 
residual upper limb paresis after completion of all inpatient reha-
bilitation. Subjects have to be able to lift the paretic arm against 
gravity (>30° of flexion or abduction), don/doff the devices on 
both wrists independently or with the assistance of a caregiver, and 
provide informed consent as documented by signature. Patients 
will be excluded from this study if they have major untreated 
depression, severe cognitive impairment, comprehensive apha-
sia, and/or severely impaired sensation (unable to feel a soft 
touch on the dorsal side of their paretic wrist with closed eyes). 
Other exclusion criteria are a potential non-compliance such as 
hospitalization during the study period, known intolerance to 
the device material, known drug or alcohol abuse, and/or other 
major comorbidities (e.g., cardiopulmonary disease, renal failure, 
hepatic dysfunction, and orthopedic disorders of the upper limb).
Stepwise Procedures
Subjects will be recruited at three study centers in Switzerland: 
University Hospital Zurich (academic hospital), cereneo—Center 
for Neurology and Rehabilitation (rehabilitation clinic), and 
Zürcher RehaZentrum Wald (rehabilitation clinic) by the local 
principal or sub-investigator. The participant timeline is displayed 
in Figure 1. The written participant information and informed 
consent forms (in German) can be obtained by the corresponding 
author. After having obtained participant consent, the baseline 
assessment (T0) will be performed. Randomization will take 
place after the baseline assessment and depending on the group 
allocation, participants will be handed over the trial arm-specific 
devices and receive instructions accordingly. Randomization 
and device hand-over will be performed by study personnel 
not involved in assessments (e.g., physical therapist and study 
nurse). The intervention period has a total duration of 6 weeks. 
The post-intervention assessment (T1) takes place at day 45 ± 3 
after baseline and the follow-up assessment (T2) at day 90 ± 6 
after baseline.
Recruitment started in September 2017 and is expected to 
last until December 2018, which means that the estimated study 
completion will be in March 2019. If inclusion stays behind, 
ethical approval will be obtained for adding other study centers 
in order to enroll the required number of patients within this 
timeframe. No payment will be provided to the participants other 
than compensation for travel costs.
interventions
The investigational devices to be used in the study are (see 
Figure 2):
•	 motion tracker “ARYS™ me|tracker” (Figure 2A: black-silver 
tracker); and
•	 motion tracker “ARYS™ pro|tracker healthy” (Figure  2B: 
black-brown tracker).
Additionally, the patients receive:
•	 two accessory charging stations “ARYS™|tracker charger” 
(Figure 2C);
•	 an Android smartphone with the pre-installed Application 
“ARYS™ me|app”; only for study subjects in the intervention 
group (Figure 2D); and
•	 a manual covering the following topics: study system compo-
nents, charging the trackers, placement of the trackers, when 
not to use the trackers (e.g., bathing, swimming, MRI scanning, 
and uncomfortable feeling on the wrist), Frequently Asked 
Questions regarding technical problems and cleaning, and con-
tact information. Additionally, the manual for the experimental 
group provides information regarding on-device feedback and 
reminders, use of the smartphone app, and daily goals.
The devices are manufactured and distributed by “yband 
therapy AG” and are intended for use in arm therapy of patients 
with arm movement deficiencies. The arm movement deficiencies 
may have been caused by cerebral, neurogenic, and spinal-related 
FigurE 2 | Investigational devices. Legend: (a) motion tracker “ARYS™ me|tracker”, black-silver tracker; (B) “ARYS™ pro|tracker healthy”, black-brown tracker; 
(C) accessory charging station “ARYS™|tracker charger”; (d) android smartphone with the pre-installed application “ARYS™ me|app,” here displaying the history 
of today’s Arm Activities, including provided reminders.
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disorders. The “ARYS™ me|tracker” and “ARYS™ pro|tracker 
healthy” are both CE-certified as a “Class 1 Medical Device.”
Experimental Intervention
Participants in the experimental group will wear an “ARYS™ 
me|tracker” on the paretic wrist and an “ARYS™ pro|tracker 
healthy” on the non-paretic wrist (see Figure 2). The trackers are 
hardware-wise identical and consist of: the actual tracker (silver 
with a feedback and communication module for the paretic 
side, which is deactivated for the control group); a reference 
tracker (black-brown tracker for the non-paretic side); and an 
exchangeable, flexible black wristband. Both elements are made 
out of biocompatible materials. The devices should be worn 
every day, as long as possible over a period of 6 weeks. During 
this 6-week period, a three-axis accelerometer in each device will 
constantly monitor the subjects’ arm movements. A threshold of 
0.1 g acceleration is defined for detection of movements. This raw 
acceleration data, aggregated over 1 min, will be converted on-
device in so-called “Arm Activities.” Starting from a pre-defined 
goal-value, new daily goals will be automatically calculated every 
day from the rolling average of the last 30 days plus 3% (e.g., after 
the first intervention week, patient X shows an average number 
of 100 “Arm Activities” per day. For day 8, his daily goal therefore 
becomes 103 “Arm Activities”). Patients will constantly be chal-
lenged to slightly increase their Arm Activities without ever being 
overstrained. Assuming a steady arm activity during the course 
of the day, a linear target activity line will be calculated (default 
start/end times: 8:00  a.m. to 10:00  p.m.). The already reached 
“Arm Activities” will be compared with an intermediate target 
value. After 30 min of inactivity, the “ARYS™ me|tracker” vibra-
tion engine will provide the subject on the paretic wrist with two 
short double pulses and up to four LEDs will light up in orange 
color to remind to make more use of this arm (Level 1 Reminder). 
If 30 min later, “Arm Activities” are still below the intermediate 
FigurE 3 | “Tree of Recovery.” Legend: a figurative representation of the amount of upper limb use in daily life. Arm Activities are displayed in blue numbers and the 
earned diamonds in red.
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target, a second escalation level of the reminder is triggered: five 
long vibrating pulses will be provided and up till four LEDs will 
light up in red color (Level 2 Reminder). Thereafter, the escala-
tion level is reset and starts over again with the Level 1 reminder 
next time. Additionally, by pressing the button on the “ARYS™ 
me|tracker” once, the LED lights will show the percentage of the 
daily target that is already reached (one white LED = <25%; two 
white LEDs = 25–49%; three white LEDs = 50–75%; three white 
LEDs and one blinking LED = 75–99%; four white LEDs = 100%, 
daily target reached) and the patient receives vibration feedback. 
When the patient has reached the daily target, the tracker vibrates.
Participants in the intervention group are encouraged to 
regularly check the pre-installed “ARYS™ me|app” on a standard 
commercial Android smartphone, which they have received. It 
will download “Arm Activity” data from the “ARYS™ me|tracker” 
automatically, motivate study subjects based on the concepts of 
gamification, and visualize activity data over various time inter-
vals. Patients can monitor the development of their daily targets, 
today’s progress, and provided reminders toward the daily target, 
as well as a history of all past “Arm Activities” and reminders 
presented in a day, week, month, and year view (see Figure 2D). 
Additionally, they can follow the growth of the “Tree of Recovery” 
(see Figure 3). This is a figurative representation of their amount 
of upper limb use over time, in which they earn “Diamonds” 
by fulfilling challenges of intensive activity and can use these 
“Diamonds” to water their tree to let it grow and flourish.
For using the devices, no medical and/or surgical procedures 
will be involved. However, a tight fit on the wrist will be benefi-
cial to reduce motion artifacts and to ensure that the vibration 
feedback is properly felt by the study subjects. As both devices 
are splash-waterproof, there is no need to doff the trackers 
during daily activities involving water, such as washing hands or 
showering. Thanks to the easy-to-use pin-and-tuck closure, study 
subjects should be able to don/doff the device on their own with-
out any help (see Figures 2A,B). Other than instruction through 
a non-blinded study member at one of the participating study 
sites and the information provided in the group-specific leaflet, 
no training or experience will be required to use the devices. The 
one-to-one instruction takes up to 30 minutes. Furthermore, the 
patients can always look up information in the accompanying 
manual, pose questions during the weekly telephone calls, and 
call the hotline.
Control Intervention
Subjects in the control group will use the same devices in the 
same way as the intervention group. They will wear the “ARYS™ 
me|tracker” on their paretic and the “ARYS™ pro|tracker 
healthy” on their non-paretic wrist. The “ARYS™ me|tracker” 
will have a custom firmware installed that deactivates both the 
vibration module as well as the LED-progress bar. Therefore, 
subjects in the control group will neither receive nor know about 
any feedback happening in the intervention group. They will not 
receive a smartphone with the “ARYS™ me|app.” The one-to-one 
instruction for the control intervention takes up to 15 minutes. 
Analogue to the patients in the experimental group, they can con-
sult the accompanying manual, ask questions during the weekly 
telephone calls, and, when needed, contact the hotline.
Additional Information Regarding the Interventions
To increase study compliance and adherence, both intervention 
and control group subjects will receive weekly reminder calls (six 
in total) to wear the “ARYS™|tracker” devices every day. These 
taBlE 1 | Overview of study measures.
Measure domain measured t0 i t1 t2
Primary outcome
Motor Activity Log—14 Item Version (MAL—14) (Amount of Use) Patient-reported amount of upper limb use in daily life X X X
Secondary outcomes
MAL—14 (Quality of Movement) Patient-reported quality of upper limb use in daily life X X X
Fugl-Meyer Assessment—Upper Extremity Upper limb motor function X X X
Action Research Arm Test Upper limb capacity X X X
EuroQol Five Dimensions Five Levels Questionnaire Health-related quality of life X X X
Modified Rankin Scale Global disability X X X
Global Rating of Perceived Changes Self-perceived change X X
Quantitative Sensor Data Compliance; activity counts of the paretic and non-paretic side X
Adverse Events Safety X X X X
other measures
Demographics Participant demography X
Stroke Event Data Disease characteristics X
Charlson Comorbidity Index Medical history X
National Institutes of Health Stroke Scale Neurological impairments X
Edinburgh Handedness Inventory Handedness X
Apples Test Visuospatial neglect X
Concomitant Therapy Standard rehabilitation therapy X X X
I, intervention; T0, baseline; T1, post-intervention; T2, 6-week follow-up.
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calls will be performed by an unblinded study team member. 
Additionally, there will be a hotline telephone number they can 
call when facing any technical problems. Discontinuation of the 
allocated intervention for a given trial participant will take place 
in case of, for example, occurrence of a Serious Adverse Event 
(AE) or participant request. We expect no modifications on the 
given intervention during the study. All participants are permit-
ted to receive concomitant rehabilitation interventions such as 
physical therapy and/or occupational therapy during the trial. 
The time spent in these interventions will be registered during 
the total study period.
Sample Size
A sample size calculation based on a difference between groups in 
change from baseline to post-intervention in the AOU subscale 
of the MAL—14 of 0.75 points. With an effect SD of 1.00, a two-
sided alpha level set at 0.05, and a power of 80%, 28 subjects per 
group are required (24). Taking into account an attrition rate 
of 10%, a total of 62 subjects will be randomized. In case of an 
attrition rate higher than the expected 10%, post-recruitment for 
replacement will take place.
Measures
Potential participants will be screened and examined by the local 
study team for eligibility. Included subjects will be assessed prior 
to randomization (T0), after the 6-week intervention (T1), and 
6  weeks thereafter (T2). The outcome assessors will be trained 
regarding the assessments and are blinded to group allocation. 
Study participants will be told at the beginning of the study, 
as well as right before and during the T1 and T2 assessments, 
not to mention any details regarding their experiences with the 
devices during the assessment visits. Potential success or failure 
of blinding will be checked, by asking the assessors at the end of 
the post-intervention and follow-up visits, in which group they 
think a given patient was allocated. Success of blinding will be 
presented in a descriptive manner.
Primary endpoint is the change from T0 to T1. An overview of 
the measures and timing of assessments is displayed in Table 1. 
Data collection forms (in German) can be obtained by the cor-
responding author upon request.
Primary Outcome
The primary outcome measure of the present study is the 
patient-reported amount of use of the paretic upper limb in daily 
life, measured with the MAL—14 AOU subscale (24–26). In a 
semi-structured interview, the patient is questioned regarding 
how often he or she has used the paretic upper limb during 14 
activities of daily living (ADL) tasks on a six-point ordinal scale. 
For each item, the score ranges from 0 [did not use my weaker 
arm (not used)] to 5 [used my weaker arm as often as before the 
stroke (same as pre-stroke)]. Scores are only given if the patient 
has performed the ADL task during the last week. The total score 
for the MAL—14 AOU subscale ranges from 0 to 5, calculated by 
adding scores for each of the performed items and subsequently 
dividing this number by the total number of performed tasks.
Secondary Outcomes
The secondary outcome measures include the FMA—UE, 
Action Research Arm Test (ARAT), EuroQol Five Dimensions 
Five Levels Questionnaire (EQ-5D-5L), modified Rankin Scale 
(mRS), MAL—14 Quality of Movement (QOM) subscale, Global 
Rating of Perceived Changes (GRPC), Quantitative Sensor Data 
for compliance and Arm Activities of the paretic and non-paretic 
upper limb during the 6-week intervention, and AEs.
Fugl-Meyer Assessment—Upper Extremity Subscale
The FMA-UE measures motor function of the paretic upper 
limb (27, 28). A total of 33 items are assessed and each item 
is rated on a three-point ordinal scale (0 =  cannot perform, 
7Held et al. Encouraging Real-World Upper Limb Use
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1 = performs partially, and 2 = performs fully). The sum score 
ranges from 0 to 66.
Action Research Arm Test
Upper limb capacity is measured with the ARAT and includes four 
categories: grasp (six items), grip (four items), pinch (six items), 
and gross movement (three items) (29–31). Each item is rated on 
a four-point ordinal scale (0 = no movement; 1 = the movement 
task is partially performed; 2 = the movement task is completed, 
but takes abnormally long; and 3 = the movement is performed 
normally), leading to a maximum overall score of 57 points.
EuroQol Five Dimensions Five Levels Questionnaire
The EQ-5D-5L is a self-completed questionnaire regarding 
health-related quality of life (32, 33). Each of the five assessed 
domains (mobility, self-care, usual activities, pain/discomfort, 
and anxiety/depression) is described by one out of five responses, 
ranging from “no problem/not at all” to “unable/major problem.” 
In addition, the patient is asked to rate his or her self-rated health 
on a Visual Analog Scale. Approval of the EuroQol Research 
Foundation to use the German (Switzerland) EQ-5D-5L paper 
version has been obtained (March 13, 2017).
Modified Rankin Scale
Global disability is assessed with the mRS, which includes an 
informal interview with the patient, to rate the extent of a patient’s 
post-stroke disability or impairment in ADLs on a six-point ordi-
nal scale, ranging from 0 = “no symptoms at all” to 5 = “severe 
disability” (34–36).
Motor Activity Log—14 Item Version—Quality of Movement 
Subscale
The MAL—14 QOM measures the patient-reported quality of 
paretic upper limb use in daily life by performing a semi-struc-
tured interview (24–26). Analogue to the AOU subscale, 14 ADL 
tasks are questioned. Patients score how well the paretic upper 
limb helped during this activity on a six-point ordinal scale, with 
item scores ranging from 0 [my weaker arm was not used at all 
for that activity (not used)] to 5 [the ability to use my weaker arm 
for that activity was as good as before the stroke (normal)], and a 
total score ranging from 0 to 5.
Global Rating of Perceived Changes
With the GRPC, the patients rate their perceived changes in the 
daily life usage of the paretic upper limb, using the following 
seven-point Likert scale: score 1 is much better; score 2 = a lit-
tle better, meaningful; score 3 = a little better, not meaningful; 
score 4 = about the same; score 5 = a little worse, not meaning-
ful; score 6 =  a little worse, meaningful; and score 7 = much 
worse (37).
Quantitative Sensor Data for Compliance and Activity Counts
Adherence will be monitored through the weekly reminder calls 
and through analysis of the gathered Quantitative Sensor Data 
and smartphone App usage data. The Quantitative Sensor Data 
measure the “Arm Activities” by using the acceleration data, 
aggregated over 1 min during wearing the activity tracker. This 
refers to Arm Activities of both the paretic and non-paretic side 
and allows comparing both changes in Arm Activities over time 
for each upper limb during the 6-week intervention, as well as 
comparing Arm Activities between the paretic and non-paretic 
upper limb.
Safety
Adverse Events will be gathered from inclusion upon follow-up. 
Assessments will be made during each study visit, as well as by 
the weekly phone calls during the intervention period. Each time, 
study subjects will be actively questioned by unblinded study per-
sonnel whether they experienced any AEs. In case of occurrence 
of a related AE, the time of onset, the duration, the resolution, 
actions that were taken, the intensity as well as the relationship 
with the study intervention will be recorded.
Descriptive Measures
Next to the above described outcome measures, the following 
data will be collected at baseline to characterize our cohort: 
demographic data, stroke event data, comorbidities, handedness 
[Edinburgh Handedness Inventory (38)], neglect [Apples Test 
(39)], social situation, and neurological functions [National 
Institutes of Health Stroke Scale (40)].
data Collection
Assessments will take place at one of the participating centers, 
or at the patients’ home when he or she is not able to visit one of 
the study centers. All assessors will be trained prior to the first 
screening during which they will receive proper instruction and 
guidance regarding all outcome parameters and assessments that 
will be taken. The trial management committee (TMC) will be 
available for questions.
In the case that a patient discontinues or deviates from the 
intervention protocol, all efforts will be made to obtain at least 
the primary outcome measure (MAL—14 AOU) and the safety 
measures (AEs) at the pre-defined study visits. All patients will 
receive a reminder for each visit to diminish retention and incom-
plete follow-up.
data Management
Study data will be recorded in electronic Case Report Forms 
(eCRF). For each enrolled study participant, an eCRF will be 
maintained. These eCRFs will be kept current to reflect subject 
status at each phase during the course of study. The participants’ 
code will be assigned in a random order. Source data will be 
available at the respective study site to document the existence of 
the study participants. Source data will include the original docu-
ments relating to the study, as well as the medical treatment and 
medical history of the participant. All study data will be archived 
for a minimum of 10 years after study termination or pre-mature 
termination of the clinical trial in a secure database. Study data 
will be managed using REDCap™, being hosted on servers 
administered by the Data Informatics Services Core of cereneo 
Schweiz AG. To access the REDCap™ site, all study team users 
of the REDCap™ system will be issued a unique username and 
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password that is generated and maintained by our administrator 
on the REDCap™ server.
The study data will be analyzed by the TMC after study 
completion (last patient, last visit). No interim analysis will be 
performed. Only the study coordinators and principle investiga-
tors will have access to the final trial dataset.
Statistical analysis
Patient demographics and baseline data will be analyzed by trial 
arm using summary descriptive statistics. Baseline differences 
between groups will be tested by the independent-samples t-test 
for parametric data, Pearson’s χ2 test for categorical data, and the 
Mann–Whitney U test for non-parametric data.
Differences in change scores (T0–T1) between groups will 
be analyzed for the primary outcome (MAL—14 AOU) and 
secondary outcomes (MAL—14 QOM, FMA—UE, ARAT, 
EQ-5D-5L, mRS, and Quantitative Sensor Data). In addition, 
change will be monitored in the follow-up assessments (T1–T2). 
An analysis of covariance will be applied, with the baseline value 
of the measure of interest as a covariate. Compliance to using 
the devices during the 6-week intervention period and safety 
data will be presented by trial arm with descriptive statistics and 
compared between groups by the independent-samples t-test, 
Pearson’s χ2 test, or Mann–Whitney U test, depending on the 
nature of the data distribution. In a secondary analysis, compli-
ance to wearing the trackers—based on the Quantitative Sensor 
Data—will be added as a covariate for analysis of the primary 
outcome MAL-14 AOU.
All randomized subjects will be included in the analyses 
according to the intention-to-treat approach. Missing data will 
be imputed. In addition, differences in baseline characteristics of 
patients who did and did not dropout will be formally tested. A 
p-value of <0.05 will be considered to be statistically significant. 
The analyses will be performed in IBM SPSS Statistics 23.
Furthermore, the compliance to the intervention will be pre-
sented with descriptive statistics. The MCID will be calculated 
based on the MAL—14 AOU and GRPC scores, analogue to 
previous work by Lang et al. (37).
Monitoring and Quality Control
The sponsor–investigator has the overall responsibility for the 
study conduct. The TMC at the University Hospital Zurich pro-
vides day-to-day support for the sites.
Regular monitoring visits at the investigator’s site prior to the 
start and during the course of the study will help to follow-up 
the progress of the clinical study, to assure utmost accuracy of 
the data, and to detect possible errors at an early time point. All 
original data including patient files, progress notes, and copies of 
laboratory and medical test results will be available for monitor-
ing. The monitor will review all or a part of the eCRFs and written 
informed consent forms. The accuracy of the data will be verified 
by reviewing the above referenced documents. A formal Data 
Monitoring Committee or equivalent body will not be convened, 
as the study is approved by the ethical committees as a clinical 
trial with a CE-marked Medical Device with minimal risks. 
However, safety data will prospectively be reviewed at monthly 
TMC meetings.
The entered data will be verified by an independent unblinded 
study nurse, after a block of 10 subjects have been enrolled in the 
study.
audits and inspections
A quality assurance audit/inspection of this study may be 
conducted by the Competent Authority or Competent Ethics 
Committee, respectively. The quality assurance auditor/inspector 
will have access to all medical records, the investigator’s study-
related files and correspondence, and the informed consent 
documentation that is relevant to this clinical study. The inves-
tigator will allow the persons being responsible for the audit or 
the inspection to have access to the source data/documents and 
to answer any questions arising. All involved parties will keep the 
patient data strictly confidential.
The primary endpoint (MAL—14 AOU) and AEs will be 
monitored by the TMC.
anticipated results
We expect that a 6-week program of wearing a wrist-worn activ-
ity tracking device, providing multimodal feedback on daily life 
arm use will induce statistically significant and clinical relevant 
changes in daily life upper limb use, when compared with wearing 
a sham device in patients who are beyond 3 months post-stroke.
diSCuSSion
By applying a wrist-worn activity tracking and feedback device, 
this study aims to optimize patient-reported amount of daily life 
upper limb use in stroke survivors beyond the first 3  months 
after stroke onset. Patients are eligible, regardless whether they 
have suffered an ischemic or hemorrhagic stroke. Although it has 
been shown that hemorrhagic stroke patients are more severely 
affected in the acute stage when compared with ischemic stroke 
patients (41), long-term functional outcomes were not signifi-
cantly different (41, 42). As we include stroke survivors beyond 
3 months post-stroke, we do not expect that type of stroke affects 
the outcomes of the present study. In addition, since we will 
recruit stroke patients beyond 3  months after stroke onset, we 
do expect that recovery has plateaued and no improvements will 
occur in the absence of intensive rehabilitation.
Previous studies have shown that intensive rehabilitation can 
influence upper limb capacity in chronic stroke patients, but con-
text-specificity is often limited and the observed improvements 
fail to translate to upper limb use in daily life (10). The present 
study can help to close the gap that exists regarding the translation 
of gains made during inpatient rehabilitation to the home situa-
tion. The amount that patients use their paretic arm in daily life 
could be enhanced by providing multimodal feedback when they 
are in their home environment. Feedback can be used to motivate 
stroke patients and with that, positively impact patient outcomes 
(43). The experimental trial arm receives feedback regarding 
Arm Activities (i.e., knowledge of results). This can mainly be 
seen as extrinsic feedback, as the patients receive immediate 
vibrotactile feedback from the trackers when paretic arm use is 
below the pre-set daily target (i.e., controlled motivation). They 
furthermore receive delayed feedback regarding paretic arm use 
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when they use the smartphone application. However, the use of 
the pre-installed application on the smartphone also requires 
self-determined motivation (i.e., self-control of feedback) of the 
patient, as he or she actively has to open the application for check-
ing their progress and play the “Tree of Recovery.” We expect that 
the combination of various forms of feedback (vibrotactile feed-
back, visual feedback by the LED lights, information regarding 
upper limb activity counts in the app, and gamification) increases 
patient-reported amount of upper limb use in daily life, which 
consolidates at follow-up.
The applied tracking and feedback device focuses on the 
number of times that the patient moves the paretic upper limb 
in daily life. The MAL—14 AOU as a primary outcome matches 
this goal, by asking patients to rate how often they have used their 
paretic upper limb in daily life activities. We hypothesize that the 
change in MAL—14 AOU from baseline to post-intervention and 
follow-up will significantly differ between the experimental and 
control groups, favoring the experimental group. We expect that 
this difference will be also clinically relevant. This means that 
the change observed in the experimental group from baseline to 
post-intervention is at least 0.75 points more when compared with 
the control group. The latter is especially important, as clinical 
applicability and acceptability are highly dependent on whether 
a statistically significant difference is also meaningful for clinical 
practice. Although this study is not powered for our secondary 
outcomes, we expect to see relevant differences between groups 
regarding upper limb capacity (ARAT) and changes in upper limb 
activity counts as measured by the tracker devices itself during 
the 6-week intervention. Contrary, we do not expect to find clini-
cally relevant change on motor function of the paretic upper limb 
(FMA—UE). First of all, because the feedback does not relate to 
QOM. Second, while patients in the chronic phase usually do not 
show significant, clinically relevant changes on motor function 
beyond 3 months post-stroke (44, 45). Furthermore, we do not 
expect to see a difference between groups regarding safety and 
compliance to wear the devices.
A positive result of this study will underline the importance 
of tracking and feedback on daily life upper limb use after stroke. 
It would provide therapists with a tool to enhance their patients’ 
real-world upper limb use, without being labor-intensive. 
Furthermore, the application of a tracking and feedback device 
could potentially reduce healthcare costs, although that is some-
thing that is beyond the scope of the present study.
EtHiCS and diSSEMination
This study will be carried out in compliance with the protocol 
approved by the previously mentioned ethical committees (ver-
sion 1.1, dated 20/07/2017), the current version of the Declaration 
of Helsinki, the ICH-GCP or ISO 14155:2011, as well as all Swiss 
national legal and regulatory requirements. All subjects will give 
written informed consent in accordance with the Declaration 
of Helsinki. The trial is registered at https://clinicaltrials.gov, 
unique identifier NCT03294187. When protocol amendments 
are needed (e.g., to include another participating center), 
ethical approval will be obtained first. After having obtained this 
approval, relevant adaptations will be made in the relevant clini-
cal trial registry databases.
Potentially eligible participants will be screened by the study 
site principal or sub-investigator for the presence of a first stroke 
>90 days, their ability to lift the paretic arm against gravity (>30° 
flexion or abduction), to don/doff the “ARYS™|tracker” devices 
independently on both wrists or if not, whether a caregiver is at 
hand for assistance, and to feel a soft touch on the dorsal side 
of their paretic wrist with closed eyes. Additionally, potential 
participants will be questioned and their medical record will be 
checked in regard to the other eligibility criteria. Given eligibility 
to take part in the study, they will be provided with further details 
and an informed consent form by one of the study members. The 
model consent form and other related documentation given to 
participants (all in German) can be obtained by the correspond-
ing author upon request.
A separate list with patients screened, but who are not enrolled 
will contain information regarding the number of patients and 
the reasons for not enrolling. This list will be stored in the Trial 
Master File or Investigator Site File and is only accessible by the 
research team and the persons responsible for monitoring, audits, 
or inspections.
After the statistical analysis of this trial, the sponsor will 
make every effort to publish the data in a peer-reviewed medical 
journal, thereby adhering to the CONSORT reporting standards 
(46) and SPIRIT guidelines (47). The use of professional writ-
ers is not foreseen. Authorship eligibility is defined according 
to the International Committee of Medical Journal Editors. 
Furthermore, presentations at congresses and reporting in a 
patient and healthcare professional magazine are planned.
EtHiCS StatEMEnt
The study is approved by the Cantonal Ethics Committees 
Zurich, and Northwest and Central Switzerland (BASEC-
number 2017-00948) and registered in https://clinicaltrials.
gov (NCT03294187) before recruitment started. This study will 
be carried out in compliance with the Declaration of Helsinki, 
ICH-GCP, ISO 14155:2011, and Swiss legal and regulatory 
requirements.
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